{"id":"regorafenib-bay73-4506","safety":{"commonSideEffects":[{"rate":"47","effect":"Hand-foot skin reaction"},{"rate":"34","effect":"Diarrhea"},{"rate":"32","effect":"Fatigue"},{"rate":"28","effect":"Hypertension"},{"rate":"26","effect":"Rash"},{"rate":"16","effect":"Mucositis"},{"rate":"13","effect":"Hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL1946170","moleculeType":"Small molecule","molecularWeight":"482.82"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Regorafenib inhibits a broad spectrum of kinases including VEGFR1-3, FGFR, TIE2, KIT, RET, RAF-1, and BRAF. By targeting both tumor vasculature (angiogenesis) and tumor cell proliferation pathways, it disrupts multiple mechanisms that support tumor growth and progression. This multikinase approach is particularly effective in advanced colorectal and gastrointestinal stromal tumors.","oneSentence":"Regorafenib is a multikinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor angiogenesis, stromal signaling, and oncogenic signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:19.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (second-line or later)"},{"name":"Gastrointestinal stromal tumor (GIST) after imatinib and sunitinib failure"},{"name":"Hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT06902246","phase":"PHASE2","title":"Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2026-05-01","conditions":"Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05395741","phase":"PHASE1, PHASE2","title":"Regorafenib in Patients With Refractory Primary Bone Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Mother and Child, Warsaw, Poland","startDate":"2022-04-28","conditions":"Osteosarcoma, Ewing Sarcoma of Bone","enrollment":30},{"nctId":"NCT06246643","phase":"PHASE2","title":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-01-24","conditions":"Solid Malignant Tumors","enrollment":13},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT02310477","phase":"","title":"Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2014-02","conditions":"Metastatic Colorectal Cancer","enrollment":704},{"nctId":"NCT01900743","phase":"PHASE2","title":"Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2013-06-05","conditions":"Sarcoma","enrollment":219},{"nctId":"NCT04777851","phase":"PHASE3","title":"Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7","status":"TERMINATED","sponsor":"Translational Research in Oncology","startDate":"2023-10-11","conditions":"Carcinoma, Hepatocellular","enrollment":45},{"nctId":"NCT04327700","phase":"PHASE2","title":"Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-01-26","conditions":"Hepatocellular Carcinoma","enrollment":2},{"nctId":"NCT04757363","phase":"PHASE2","title":"A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-11","conditions":"Esophagogastric Cancer, HER2-Negative","enrollment":39},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06137170","phase":"","title":"A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-03-01","conditions":"Metastatic Colorectal Cancer","enrollment":121},{"nctId":"NCT07223567","phase":"PHASE2","title":"A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-27","conditions":"Rectal Cancer, Rectal Cancer Recurrent","enrollment":""},{"nctId":"NCT04055220","phase":"NA","title":"Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2020-03-03","conditions":"Bone Sarcoma, Osteosarcoma, Ewing Sarcoma","enrollment":168},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT06558773","phase":"PHASE2","title":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-01","conditions":"Colorectal Cancer","enrollment":120},{"nctId":"NCT03712943","phase":"PHASE1","title":"Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-23","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, Colon Cancer","enrollment":52},{"nctId":"NCT05198934","phase":"PHASE3","title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-04-19","conditions":"Colorectal Cancer (CRC)","enrollment":160},{"nctId":"NCT04776148","phase":"PHASE3","title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-29","conditions":"Colorectal Neoplasms","enrollment":563},{"nctId":"NCT05731947","phase":"PHASE1, PHASE2","title":"Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2023-04-04","conditions":"Colorectal Cancer, Solid Tumors","enrollment":42},{"nctId":"NCT05672316","phase":"PHASE1, PHASE2","title":"Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-05-11","conditions":"Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma","enrollment":28},{"nctId":"NCT04362839","phase":"PHASE1","title":"Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-05-27","conditions":"Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma","enrollment":39},{"nctId":"NCT05155189","phase":"PHASE1","title":"A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2022-02-21","conditions":"Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT07328009","phase":"PHASE2","title":"A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT06006923","phase":"PHASE2","title":"Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer","status":"TERMINATED","sponsor":"Anwaar Saeed","startDate":"2024-06-26","conditions":"MSI-H Colorectal Cancer","enrollment":1},{"nctId":"NCT06087263","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-18","conditions":"Gastrointestinal Stromal Tumors","enrollment":3},{"nctId":"NCT03844620","phase":"PHASE2","title":"Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-29","conditions":"Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8","enrollment":100},{"nctId":"NCT03042689","phase":"PHASE1","title":"Study of Regorafenib in Patients With Advanced Myeloid Malignancies","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-04-17","conditions":"Acute Myeloid Leukemia","enrollment":16},{"nctId":"NCT07213570","phase":"PHASE2","title":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-10-16","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT02955940","phase":"PHASE2","title":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2016-11-30","conditions":"Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer","enrollment":10},{"nctId":"NCT05600309","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-06-14","conditions":"Colorectal Cancer","enrollment":94},{"nctId":"NCT06454409","phase":"PHASE1","title":"Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2025-05-21","conditions":"Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":20},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":818},{"nctId":"NCT05425940","phase":"PHASE3","title":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2022-09-07","conditions":"Colorectal Cancer","enrollment":901},{"nctId":"NCT05064059","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-10","conditions":"Colorectal Cancer","enrollment":441},{"nctId":"NCT02389244","phase":"PHASE2","title":"A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-09","conditions":"Ewing Sarcomas, Chondrosarcomas, Osteosarcomas","enrollment":163},{"nctId":"NCT02657551","phase":"PHASE2","title":"A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-01","conditions":"Thyroid Cancer","enrollment":8},{"nctId":"NCT05366816","phase":"PHASE2","title":"ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-10-17","conditions":"Gastrointestinal Stromal Tumors","enrollment":48},{"nctId":"NCT03970447","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2019-07-30","conditions":"Glioblastoma","enrollment":1280},{"nctId":"NCT05194293","phase":"PHASE2","title":"Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2023-07-01","conditions":"Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8","enrollment":4},{"nctId":"NCT06887218","phase":"PHASE2","title":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-08","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":57},{"nctId":"NCT05328908","phase":"PHASE3","title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-04-28","conditions":"Colorectal Neoplasms","enrollment":770},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT03657641","phase":"PHASE1, PHASE2","title":"Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2019-06-21","conditions":"Colorectal Cancer, Colorectal Cancer Metastatic","enrollment":75},{"nctId":"NCT02368886","phase":"PHASE2","title":"Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2015-03-27","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7","enrollment":123},{"nctId":"NCT06321055","phase":"","title":"An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-03-01","conditions":"Advanced Gastrointestinal Stromal Tumor","enrollment":136},{"nctId":"NCT04696055","phase":"PHASE2","title":"Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-03","conditions":"Hepatocellular Carcinoma","enrollment":95},{"nctId":"NCT06949982","phase":"PHASE2","title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","status":"RECRUITING","sponsor":"Sergey Orlov, MD","startDate":"2025-03-17","conditions":"Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms","enrollment":60},{"nctId":"NCT04704154","phase":"PHASE2","title":"A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-03","conditions":"Solid Tumors","enrollment":175},{"nctId":"NCT04450836","phase":"PHASE2","title":"Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2020-11-23","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT03899428","phase":"PHASE2","title":"Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC","status":"RECRUITING","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-02","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT03627728","phase":"PHASE2","title":"Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2018-06-13","conditions":"Gastric Cancer","enrollment":67},{"nctId":"NCT05770882","phase":"PHASE1, PHASE2","title":"Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"Great Novel Therapeutics Biotech & Medicals Corporation","startDate":"2023-04-25","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":7},{"nctId":"NCT06029010","phase":"","title":"An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-08-31","conditions":"Metastatic Colorectal Cancer","enrollment":2326},{"nctId":"NCT06829355","phase":"PHASE2","title":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-02-11","conditions":"MCRC","enrollment":52},{"nctId":"NCT03406871","phase":"PHASE1","title":"Regorafenib and Nivolumab Simultaneous Combination Therapy","status":"COMPLETED","sponsor":"Kohei Shitara","startDate":"2018-01-15","conditions":"Advanced and Metastatic Solid Tumor","enrollment":50},{"nctId":"NCT04534218","phase":"PHASE2","title":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2020-10-16","conditions":"Colo-rectal Cancer, Metastatic Cancer","enrollment":49},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT03564938","phase":"PHASE4","title":"Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-07-30","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT04701476","phase":"PHASE2","title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","status":"RECRUITING","sponsor":"Teclison Ltd.","startDate":"2021-05-20","conditions":"Colorectal Cancer; Lung Cancer","enrollment":110},{"nctId":"NCT06575725","phase":"PHASE2","title":"Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2024-11-01","conditions":"Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT02096354","phase":"PHASE2","title":"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2014-05","conditions":"Colorectal Neoplasms","enrollment":62},{"nctId":"NCT02175095","phase":"NA","title":"[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2014-07-18","conditions":"Colorectal Cancer","enrollment":68},{"nctId":"NCT04117945","phase":"PHASE2","title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-03-03","conditions":"BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma","enrollment":22},{"nctId":"NCT05963490","phase":"PHASE2","title":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":108},{"nctId":"NCT02466009","phase":"PHASE2","title":"Regorafenib in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT05159245","phase":"PHASE2","title":"The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2021-12-10","conditions":"Advanced Cancer, Solid Tumor, Haematological Malignancy","enrollment":250},{"nctId":"NCT05394740","phase":"PHASE1, PHASE2","title":"Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-06-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":30},{"nctId":"NCT02581059","phase":"PHASE2","title":"Efficacy of Ginseng for Patients on Regorafenib","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-04","conditions":"Colorectal Cancer, Palliative Medicine, Supportive Care","enrollment":10},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT03992456","phase":"PHASE2","title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-04-24","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":12},{"nctId":"NCT05900648","phase":"PHASE2","title":"Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-17","conditions":"Colorectal Cancer, Colon Cancer, Rectum Cancer","enrollment":""},{"nctId":"NCT02085148","phase":"PHASE1","title":"A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-04-11","conditions":"Pediatric Oncology","enrollment":62},{"nctId":"NCT03890731","phase":"PHASE2","title":"A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-04-02","conditions":"Solid Cancer","enrollment":6},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04810182","phase":"","title":"Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2020-09-10","conditions":"Glioblastoma Multiforme","enrollment":192},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT02316340","phase":"PHASE2","title":"Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2015-02-11","conditions":"Colorectal Cancer","enrollment":42},{"nctId":"NCT02795156","phase":"PHASE2","title":"Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-09-28","conditions":"Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon","enrollment":100},{"nctId":"NCT02195011","phase":"PHASE2","title":"Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2014-07","conditions":"Colorectal Neoplasms","enrollment":26},{"nctId":"NCT02024607","phase":"PHASE1, PHASE2","title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-01","conditions":"Advanced Gastrointestinal Cancer","enrollment":495},{"nctId":"NCT03215264","phase":"PHASE1","title":"To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-10-02","conditions":"Colorectal Cancer","enrollment":20},{"nctId":"NCT05594147","phase":"","title":"An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-10-31","conditions":"Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19), SARS-CoV-2 Infection","enrollment":4103},{"nctId":"NCT02383433","phase":"PHASE2","title":"Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2016-06-14","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":2},{"nctId":"NCT06089330","phase":"PHASE2","title":"A Study of JMT101 in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":102},{"nctId":"NCT03722108","phase":"PHASE1, PHASE2","title":"Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2019-02-07","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction","enrollment":89},{"nctId":"NCT02584465","phase":"PHASE2","title":"REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2015-08-28","conditions":"Ovarian Carcinoma","enrollment":68},{"nctId":"NCT03520842","phase":"PHASE2","title":"Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-08-14","conditions":"KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma","enrollment":22},{"nctId":"NCT03347292","phase":"PHASE1","title":"Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-18","conditions":"Carcinoma, Hepatocellular","enrollment":58},{"nctId":"NCT02106858","phase":"","title":"Stivarga Regulatory Post-Marketing Surveillance Study in Korea","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06-25","conditions":"Colorectal Neoplasms","enrollment":316},{"nctId":"NCT04126733","phase":"PHASE2","title":"Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-14","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT03289273","phase":"","title":"Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-13","conditions":"Liver Neoplasms","enrollment":1010},{"nctId":"NCT05877001","phase":"PHASE2","title":"The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-05-30","conditions":"Colorectal Liver Metastases","enrollment":20},{"nctId":"NCT05382741","phase":"PHASE2","title":"Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial","status":"UNKNOWN","sponsor":"Ospedale Policlinico San Martino","startDate":"2022-03-02","conditions":"Colorectal Cancer Stage IV, No Evidence of Disease State","enrollment":182},{"nctId":"NCT05048017","phase":"PHASE2","title":"Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor","enrollment":20},{"nctId":"NCT02638766","phase":"PHASE2","title":"Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST","status":"COMPLETED","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2015-11","conditions":"Gastrointestinal Stromal Tumors","enrollment":15},{"nctId":"NCT05551039","phase":"","title":"An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-08-15","conditions":"Metastatic Colorectal Cancer","enrollment":300},{"nctId":"NCT02910843","phase":"PHASE1","title":"Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2017-02-22","conditions":"Rectal Cancer","enrollment":25},{"nctId":"NCT03465722","phase":"PHASE3","title":"(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST","status":"COMPLETED","sponsor":"Blueprint Medicines Corporation","startDate":"2018-03-26","conditions":"GIST","enrollment":476}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Regorafenib (BAY73-4506)","genericName":"Regorafenib (BAY73-4506)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regorafenib is a multikinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor angiogenesis, stromal signaling, and oncogenic signaling. Used for Metastatic colorectal cancer (second-line or later), Gastrointestinal stromal tumor (GIST) after imatinib and sunitinib failure, Hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}